Interim report May – July 2026
View reportCEO comment
The first quarter of our new financial year clearly shows that Integrum continues to develop in the right direction. After a year marked by extensive changes, we now see how our strategic shift is starting to take effect. The number of S1 surgeries continue to grow, revenue is increasing, and we report a positive EBITDA for the quarter.
The quarter in figures
Stage 1 (S1)
Surgeries
48
Net sales
SEK million
30.2
EBITDA
SEK million
3.8
Operating cash flow
SEK million
-2.2
How Stacey got her life back
Stacey's life with the OPRA™ Implant System
Stacey is not very good at sitting still. She runs her own salon, loves horses and riding, and wants to be there when things are happening. Her leg amputation changed what was possible. Today, after treatment with Integrum's OPRA™ Implant System, her everyday life looks completely different.
